10-K Filing

IMMIX BIOPHARMA, INC. CIK: 1873835 FY 2023

Filing Information

Form Type	10-K
Accession Number	`0001493152-24-011975`
Period End Date	20231231
Filing Date	20240329
Fiscal Year	2023
Fiscal Period	FY
XBRL Instance	form10-k_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 63 Income Statement 42 Cash Flow Statement 54 Stockholders Equity 25

Balance Sheet 63 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$17.51M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$13.44M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Tax receivable	`IncomeTaxReceivable`	$1.17M	USD	Point-in-time
Tax receivable	`IncomeTaxReceivable`	$255.71K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common stock par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.21M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.11M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$19.79M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$14.90M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	19.99M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	13.96M	shares	Point-in-time
Deferred offering costs	`DeferredCosts`	$87.23K	USD	Point-in-time
Deferred offering costs	`DeferredCosts`	$6.72K	USD	Point-in-time
Equipment, net	`PropertyPlantAndEquipmentNet`	$3.56K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	13.89M	shares	Point-in-time
Equipment, net	`PropertyPlantAndEquipmentNet`	$50.18K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	19.92M	shares	Point-in-time
Total assets	`Assets`	$19.93M	USD	Point-in-time
Treasury stock, shares	`TreasuryStockCommonShares`	72,363.00	shares	Point-in-time
Treasury stock, shares	`TreasuryStockCommonShares`	72,363.00	shares	Point-in-time
Total assets	`Assets`	$14.91M	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$3.72M	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.27M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.27M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$3.72M	USD	Point-in-time
Funds held for subsidiary private offering	`FundsHeldForSubsidiaryPrivateOfferingNonCurrent`	$475.00K	USD	Point-in-time
Funds held for subsidiary private offering	`FundsHeldForSubsidiaryPrivateOfferingNonCurrent`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$1.75M	USD	Point-in-time
Total liabilities	`Liabilities`	$3.72M	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $0.0001 par value; 200,000,000 shares authorized; 19,994,719 shares issued and 19,922,356 shares outstanding at December 31, 2023, and 13,964,485 shares issued and 13,892,122 shares outstanding at December 31, 2022	`CommonStockValue`	$1.40K	USD	Point-in-time
Common stock, $0.0001 par value; 200,000,000 shares authorized; 19,994,719 shares issued and 19,922,356 shares outstanding at December 31, 2023, and 13,964,485 shares issued and 13,892,122 shares outstanding at December 31, 2022	`CommonStockValue`	$2.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$69.78M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$51.16M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$134.67K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$87.02K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-37.99M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-53.41M	USD	Point-in-time
Treasury stock at cost, 72,363 shares as of December 31, 2023 and 2022	`TreasuryStockValue`	$99.96K	USD	Point-in-time
Treasury stock at cost, 72,363 shares as of December 31, 2023 and 2022	`TreasuryStockValue`	$99.96K	USD	Point-in-time
Total Immix Biopharma, Inc. stockholders equity	`StockholdersEquity`	$16.41M	USD	Point-in-time
Total Immix Biopharma, Inc. stockholders equity	`StockholdersEquity`	$13.16M	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	-	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$-201.74K	USD	Point-in-time
Total stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$13.16M	USD	Point-in-time
Total stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$16.20M	USD	Point-in-time
Total stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$17.99M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$19.93M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$14.91M	USD	Point-in-time

Income Statement 42 line items

Line Item	Tag	Value	Unit	Period
General and administrative expenses	`GeneralAndAdministrativeExpense`	$7.41M	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$4.02M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$4.20M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$8.74M	USD	Annual
Total operating expenses	`OperatingExpenses`	$16.14M	USD	Annual
Total operating expenses	`OperatingExpenses`	$8.22M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-16.14M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-8.22M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$572.01K	USD	Annual
Interest income	`InvestmentIncomeInterest`	-	USD	Annual
Interest expense	`InterestExpense`	-	USD	Annual
Interest expense	`InterestExpense`	$497.00	USD	Annual
Total other income (expense), net	`NonoperatingIncomeExpense`	$572.01K	USD	Annual
Total other income (expense), net	`NonoperatingIncomeExpense`	$-497.00	USD	Annual
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-8.22M	USD	Annual
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-15.57M	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$10.27K	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$26.41K	USD	Annual
Net loss	`ProfitLoss`	$-8.23M	USD	Annual
Net loss	`ProfitLoss`	$-15.60M	USD	Annual
Net loss attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-169.47K	USD	Annual
Net loss attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	-	USD	Annual
Net loss attributable to Immix Biopharma, Inc. common stockholders	`NetIncomeLoss`	$-8.23M	USD	Annual
Net loss attributable to Immix Biopharma, Inc. common stockholders	`NetIncomeLoss`	$-15.43M	USD	Annual
Foreign currency translation	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$47.65K	USD	Annual
Foreign currency translation	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-38.39K	USD	Annual
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-38.39K	USD	Annual
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$47.65K	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-8.27M	USD	Annual
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-15.38M	USD	Annual
Less: comprehensive loss attributable to non-controlling interests	`OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest`	-	USD	Annual
Less: comprehensive loss attributable to non-controlling interests	`OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToNoncontrollingInterest`	-	USD	Annual
Comprehensive loss attributable to Immix Biopharma, Inc. common stockholders	`OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest`	$-8.27M	USD	Annual
Comprehensive loss attributable to Immix Biopharma, Inc. common stockholders	`OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest`	$-15.38M	USD	Annual
Loss per common share - basic	`EarningsPerShareBasic`	$-0.59	USD	Annual
Loss per common share - basic	`EarningsPerShareBasic`	$-0.89	USD	Annual
Loss per common share - diluted	`EarningsPerShareDiluted`	$-0.59	USD	Annual
Loss per common share - diluted	`EarningsPerShareDiluted`	$-0.89	USD	Annual
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	17.34M	shares	Annual
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	13.89M	shares	Annual
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	17.34M	shares	Annual
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	13.89M	shares	Annual

Cash Flow Statement 54 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-8.23M	USD	Annual
Net loss	`ProfitLoss`	$-15.60M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$2.57M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$624.07K	USD	Annual
Depreciation	`Depreciation`	$2.13K	USD	Annual
Depreciation	`Depreciation`	$5.47K	USD	Annual
Tax receivable	`IncreaseDecreaseInIncomeTaxesReceivable`	$893.40K	USD	Annual
Tax receivable	`IncreaseDecreaseInIncomeTaxesReceivable`	$236.38K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-111.84K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$691.05K	USD	Annual
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$1.13M	USD	Annual
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$2.43M	USD	Annual
Accrued interest	`IncreaseDecreaseInInterestPayableNet`	-	USD	Annual
Accrued interest	`IncreaseDecreaseInInterestPayableNet`	$-9.10K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-11.37M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-7.41M	USD	Annual
Purchase of equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	-	USD	Annual
Purchase of equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$52.09K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-52.09K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	Annual
Payments of deferred offering costs	`PaymentOfFinancingAndStockIssuanceCosts`	$234.62K	USD	Annual
Payments of deferred offering costs	`PaymentOfFinancingAndStockIssuanceCosts`	$6.72K	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	-	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$2.62K	USD	Annual
Payments on note payable	`RepaymentsOfNotesPayable`	-	USD	Annual
Payments on note payable	`RepaymentsOfNotesPayable`	$50.00K	USD	Annual
Proceeds from sale of common stock, net of offering costs	`ProceedsFromIssuanceOfCommonStock`	$15.52M	USD	Annual
Proceeds from sale of common stock, net of offering costs	`ProceedsFromIssuanceOfCommonStock`	$2.91M	USD	Annual
Proceeds from sale of Nexcella common stock	`ProceedsFromSaleOfCommonStock`	$475.00K	USD	Annual
Proceeds from sale of Nexcella common stock	`ProceedsFromSaleOfCommonStock`	$175.00K	USD	Annual
Repurchase of common stock	`PaymentsForRepurchaseOfCommonStock`	-	USD	Annual
Repurchase of common stock	`PaymentsForRepurchaseOfCommonStock`	$99.96K	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$15.46M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$3.23M	USD	Annual
Effect of foreign currency on cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-31.52K	USD	Annual
Effect of foreign currency on cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$33.09K	USD	Annual
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-4.21M	USD	Annual
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$4.07M	USD	Annual
Cash and cash equivalents - beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$17.64M	USD	Point-in-time
Cash and cash equivalents - beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$17.51M	USD	Point-in-time
Cash and cash equivalents - beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$13.44M	USD	Point-in-time
Cash and cash equivalents - end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$17.64M	USD	Point-in-time
Cash and cash equivalents - end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$17.51M	USD	Point-in-time
Cash and cash equivalents - end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$13.44M	USD	Point-in-time
Interest paid	`InterestPaidNet`	-	USD	Annual
Interest paid	`InterestPaidNet`	$9.60K	USD	Annual
Income taxes paid	`IncomeTaxesPaidNet`	-	USD	Annual
Income taxes paid	`IncomeTaxesPaidNet`	-	USD	Annual
Nexcella shares issued for funds previously received	`SharesIssuedForFundsPreviouslyReceived`	-	USD	Annual
Nexcella shares issued for funds previously received	`SharesIssuedForFundsPreviouslyReceived`	$475.00K	USD	Annual
Deferred offering costs charged against proceeds from sale of common stock	`DeferredOfferingCostsChargedAgainstProceedsFromSaleOfCommonStock`	$147.39K	USD	Annual
Deferred offering costs charged against proceeds from sale of common stock	`DeferredOfferingCostsChargedAgainstProceedsFromSaleOfCommonStock`	-	USD	Annual
Cashless exercise of stock options	`CommonStockIssuedForCashlessExerciseOfStockOptions`	$6.00	USD	Annual
Cashless exercise of stock options	`CommonStockIssuedForCashlessExerciseOfStockOptions`	-	USD	Annual

Stockholders Equity 25 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$13.16M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$16.20M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$17.99M	USD	Point-in-time
Shares issued for cash proceeds, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$2.91M	USD	Annual
Shares issued for exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	-	USD	Annual
Shares issued for exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$2.62K	USD	Annual
Shares issued for cashless exercise of options, shares	`StockIssuedDuringPeriodSharesStockOptionsExercised`	140,992.00	shares	Annual
Shares issued for cashless exercise of options, shares	`StockIssuedDuringPeriodSharesStockOptionsExercised`	1,351.00	shares	Annual
Shares issued for services	`StockIssuedDuringPeriodValueIssuedForServices`	$622.42K	USD	Annual
Shares issued for services	`StockIssuedDuringPeriodValueIssuedForServices`	$100.00K	USD	Annual
Shares issued for services, shares	`StockIssuedDuringPeriodSharesIssuedForServices`	43,264.00	shares	Annual
Repurchase of common shares	`StockRepurchasedDuringPeriodValue`	$99.96K	USD	Annual
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$524.07K	USD	Annual
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$1.94M	USD	Annual
Net loss	`ProfitLoss`	$-8.23M	USD	Annual
Net loss	`ProfitLoss`	$-15.60M	USD	Annual
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax`	$47.65K	USD	Annual
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax`	$-38.39K	USD	Annual
Shares issued under ATM facilities for cash proceeds, net of offering costs	`StockIssuedDuringPeriodValueUnderAtmFacilitiesForCashProceedsNetOfOfferingCosts`	$5.44M	USD	Annual
Shares and warrants issued under private placement for cash proceeds, net of offering costs	`StockIssuedDuringPeriodValueSharesAndWarrantIssuedUnderPrivatePlacement`	$9.93M	USD	Annual
Nexcella shares issued for cash proceeds	`StockIssuedDuringPeriodValueOther`	$650.00K	USD	Annual
Non-controlling interests in subsidiary	`NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance`	-	USD	Annual
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$13.16M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$16.20M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$17.99M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.